GlaxoSmithKline to acquire Domantis Ltd for $454million

GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire Domantis Ltd for US$454million in cash.

Domantis, a privately owned company, was started in 2000 by the Medical Research Council and MVM Ltd.

The price is one of the highest ever paid for a private biotechnology company.

The acquisition agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and is expected to complete in January 2007.

Dr. Stephen Reeders, MVM managing partner and Domantis board member said: “We recognised that Sir Greg Winter and Dr. Ian Tomlinson were the worldwide leaders in antibody engineering.”

“We were also very fortunate in finding Bob Connelly to be CEO. He and Ian have done an outstanding job in building technology and commercial value in the company.”

Domantis Limited

Domantis Limited
Drug discovery platform

Website
www.gsk.com

Downloads

DownloadFull Press Release

Latest News

Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.

Alliance Pharma receives positive opinion for Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.